This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (203)  • Contact me when this article is cited  Related Content  • Related letter  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Ovarian Cancer  • Women's Health  • Menopause  • Alert me on articles by topic  Social Bookmarking   What's this?

Carmen Rodriguez, MD,MPH; Alpa V. Patel, MPH; Eugenia E. Calle, PhD; Eric J. Jacob, PhD; Michael J. Thun, MD,MS

JAMA. 2001;285:1460-1465.

Context  Postmenopausal estrogen use is associated with increased risk of endometrial and breast cancer, 2 hormone-related cancers. The effect of postmenopausal estrogen use on ovarian cancer is not established.

Objectives  To examine the association between postmenopausal estrogen use and ovarian cancer mortality and to determine whether the association differs according to duration and recency of use.

Design and Setting  The American Cancer Society's Cancer Prevention Study II, a prospective US cohort study with mortality follow-up from 1982 to 1996.

Participants  A total of 211 581 postmenopausal women who completed a baseline questionnaire in 1982 and had no history of cancer, hysterectomy, or ovarian surgery at enrollment.

Main Outcome Measure  Ovarian cancer mortality, compared among never users, users at baseline, and former users as well as by total years of use of estrogen replacement therapy (ERT).

Results  A total of 944 ovarian cancer deaths were recorded in 14 years of follow-up. Women who were using ERT at baseline had higher death rates from ovarian cancer than never users (rate ratio [RR], 1.51; 95% confidence interval [CI], 1.16-1.96). Risk was slightly but not significantly increased among former estrogen users (RR, 1.16; 95% CI, 0.99-1.37). Duration of use was associated with increased risk in both baseline and former users. Baseline users with 10 or more years of use had an RR of 2.20 (95% CI, 1.53-3.17), while former users with 10 or more years of use had an RR of 1.59 (95% CI, 1.13-2.25). Annual age-adjusted ovarian cancer death rates per 100 000 women were 64.4 for baseline users with 10 or more years of use, 38.3 for former users with 10 or more years of use, and 26.4 for never users. Among former users with 10 or more years of use, risk decreased with time since last use reported at study entry (RR for last use <15 years ago, 2.05; 95% CI, 1.29-3.25; RR for last use 15 years ago, 1.31; 95% CI, 0.79-2.17).

Conclusions  In this population, postmenopausal estrogen use for 10 or more years was associated with increased risk of ovarian cancer mortality that persisted up to 29 years after cessation of use.

Author Affiliations: Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, Ga.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Relationship Between Postmenopausal Hormone Replacement Therapy and Ovarian Cancer
Cristina Bosetti, Eva Negri, Silvia Franceschi, Dimitrios Trichopoulos, Valerie Beral, Carlo La Vecchia, Enrique Hernandez, Carmen Rodriguez, Eugenia E. Calle, Eric J. Jacobs, Alpa V. Patel, and Michael J. Thun
JAMA. 2001;285(24):3089-3090.
EXTRACT | FULL TEXT  

RELATED ARTICLE

March 21, 2001
JAMA. 2001;285(11):1519-1520.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Are Racial Disparities in Pancreatic Cancer Explained by Smoking and Overweight/Obesity?
Arnold et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:2397-2405.
ABSTRACT | FULL TEXT  

Differential induction of LRP16 by liganded and unliganded estrogen receptor {alpha} in SKOV3 ovarian carcinoma cells
Tian et al.
J Endocrinol 2009;202:167-177.
ABSTRACT | FULL TEXT  

Relationship between Epidemiologic Risk Factors and Hormone Receptor Expression in Ovarian Cancer: Results from the Nurses' Health Study
Hecht et al.
Cancer Epidemiol. Biomarkers Prev. 2009;18:1624-1630.
ABSTRACT | FULL TEXT  

Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk
Goodman et al.
Endocr Relat Cancer 2008;15:1055-1060.
ABSTRACT | FULL TEXT  

Behavioral Mediation of the Relationship Between Psychosocial Factors and HIV Disease Progression
Gore-Felton and Koopman
Psychosom. Med. 2008;70:569-574.
ABSTRACT | FULL TEXT  

Role of Depression, Stress, and Trauma in HIV Disease Progression
Leserman
Psychosom. Med. 2008;70:539-545.
ABSTRACT | FULL TEXT  

Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation
Corrao et al.
Ann Oncol 2008;19:150-155.
ABSTRACT | FULL TEXT  

Relation of Lifetime Trauma and Depressive Symptoms to Mortality in HIV
Leserman et al.
Am. J. Psychiatry 2007;164:1707-1713.
ABSTRACT | FULL TEXT  

Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis
Greiser et al.
Hum Reprod Update 2007;13:453-463.
ABSTRACT | FULL TEXT  

Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells
Treeck et al.
J Endocrinol 2007;193:421-433.
ABSTRACT | FULL TEXT  

Gonadotropins and Ovarian Cancer
Choi et al.
Endocr. Rev. 2007;28:440-461.
ABSTRACT | FULL TEXT  

Endocrine signaling in ovarian surface epithelium and cancer
Leung and Choi
Hum Reprod Update 2007;13:143-162.
ABSTRACT | FULL TEXT  

G Protein-Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17{beta}-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells
Albanito et al.
Cancer Res. 2007;67:1859-1866.
ABSTRACT | FULL TEXT  

Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort.
Lacey et al.
JNCI J Natl Cancer Inst 2006;98:1397-1405.
ABSTRACT | FULL TEXT  

Psychosocial Factors Predict CD4 and Viral Load Change in Men and Women With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Treatment
Ironson et al.
Psychosom. Med. 2005;67:1013-1021.
ABSTRACT | FULL TEXT  

Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review
Dietel et al.
Hum Reprod 2005;20:2052-2060.
ABSTRACT | FULL TEXT  

Endometrial Carcinoma Risks among Menopausal Estrogen plus Progestin and Unopposed Estrogen Users in a Cohort of Postmenopausal Women
Lacey et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1724-1731.
ABSTRACT | FULL TEXT  

Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Women: Recommendations from the U.S. Preventive Services Task Force
U.S. Preventive Services Task Force*
ANN INTERN MED 2005;142:855-860.
ABSTRACT | FULL TEXT  

How Trauma, Recent Stressful Events, and PTSD Affect Functional Health Status and Health Utilization in HIV-Infected Patients in the South
Leserman et al.
Psychosom. Med. 2005;67:500-507.
ABSTRACT | FULL TEXT  

Hyaluronan-CD44 Interaction with IQGAP1 Promotes Cdc42 and ERK Signaling, Leading to Actin Binding, Elk-1/Estrogen Receptor Transcriptional Activation, and Ovarian Cancer Progression
Bourguignon et al.
J. Biol. Chem. 2005;280:11961-11972.
ABSTRACT | FULL TEXT  

Transcriptional and Posttranscriptional Regulation of Fibulin-1 by Estrogens Leads to Differential Induction of Messenger Ribonucleic Acid Variants in Ovarian and Breast Cancer Cells
Bardin et al.
Endocrinology 2005;146:760-768.
ABSTRACT | FULL TEXT  

Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses
Lukanova and Kaaks
Cancer Epidemiol. Biomarkers Prev. 2005;14:98-107.
ABSTRACT | FULL TEXT  

Hormone Therapy and the Impact of Estrogen Intake on the Risk of Ovarian Cancer
Glud et al.
Arch Intern Med 2004;164:2253-2259.
ABSTRACT | FULL TEXT  

Loss of ER{beta} expression as a common step in estrogen-dependent tumor progression
Bardin et al.
Endocr Relat Cancer 2004;11:537-551.
ABSTRACT | FULL TEXT  

Involvement of Estrogen Receptor {beta} in Ovarian Carcinogenesis
Bardin et al.
Cancer Res. 2004;64:5861-5869.
ABSTRACT | FULL TEXT  

Short-term Menopausal Hormone Therapy for Symptom Relief: An Updated Decision Model
Col et al.
Arch Intern Med 2004;164:1634-1640.
ABSTRACT | FULL TEXT  

Screening for Ovarian Cancer: Recommendation Statement
U.S. Preventive Services Task Force
Ann Fam Med 2004;2:260-262.
FULL TEXT  

Serum Follicle-Stimulating Hormone and Risk of Epithelial Ovarian Cancer in Postmenopausal Women
Arslan et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1531-1535.
ABSTRACT | FULL TEXT  

Effects of Estrogen Plus Progestin on Gynecologic Cancers and Associated Diagnostic Procedures: The Women's Health Initiative Randomized Trial
Anderson et al.
JAMA 2003;290:1739-1748.
ABSTRACT | FULL TEXT  

Stromal Cell-Derived Factor 1, a Novel Target of Estrogen Receptor Action, Mediates the Mitogenic Effects of Estradiol in Ovarian and Breast Cancer Cells
Hall and Korach
Mol. Endocrinol. 2003;17:792-803.
ABSTRACT | FULL TEXT  

Risks and benefits of hormone replacement therapy: The evidence speaks
Humphries and Gill
CMAJ 2003;168:1001-1010.
ABSTRACT | FULL TEXT  

Evidence-based management options for women at increased breast/ovarian cancer risk
Pichert et al.
Ann Oncol 2003;14:9-19.
ABSTRACT | FULL TEXT  

Unlicensed and off label drug use in acute lymphoblastic leukaemia and other malignancies in children
Conroy et al.
Ann Oncol 2003;14:42-47.
ABSTRACT | FULL TEXT  

Estrogen Replacement Therapy and Risk of Ovarian Cancer in Postmenopausal Women
Burry et al.
JAMA 2002;288:2538-2539.
FULL TEXT  

Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Recommendations and Rationale
U.S. Preventive Services Task Force*
ANN INTERN MED 2002;137:834-839.
ABSTRACT | FULL TEXT  

Body Mass Index, Height, and the Risk of Ovarian Cancer Mortality in a Prospective Cohort of Postmenopausal Women
Rodriguez et al.
Cancer Epidemiol. Biomarkers Prev. 2002;11:822-828.
ABSTRACT | FULL TEXT  

Is There an Antiaging Medicine?
Butler et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2002;57:B333-338.
ABSTRACT | FULL TEXT  

Menopausal Hormone Replacement Therapy and Risk of Ovarian Cancer
Lacey et al.
JAMA 2002;288:334-341.
ABSTRACT | FULL TEXT  

Polymorphisms of the Estrogen-metabolizing Genes CYP17 and Catechol-O-methyltransferase and Risk of Epithelial Ovarian Cancer
Garner et al.
Cancer Res. 2002;62:3058-3062.
ABSTRACT | FULL TEXT  

Lack of Promotion of Estrogen-dependent Mammary Gland Tumors in vivo by an Isopropanolic Cimicifuga racemosa Extract
Freudenstein et al.
Cancer Res. 2002;62:3448-3452.
ABSTRACT | FULL TEXT  

Reproductive Hormone-Induced, STAT3-Mediated Interleukin 6 Action in Normal and Malignant Human Ovarian Surface Epithelial Cells
Syed et al.
JNCI J Natl Cancer Inst 2002;94:617-629.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and the Risk of Invasive Epithelial Ovarian Cancer in Swedish Women
Riman et al.
JNCI J Natl Cancer Inst 2002;94:497-504.
ABSTRACT | FULL TEXT  

The Decision to Take Hormone Replacement Therapy among Women with Disabilities
Becker et al.
West J Nurs Res 2002;24:264-281.
ABSTRACT  

Ligand-Selective Interactions of ER Detected in Living Cells by Fluorescence Resonance Energy Transfer
Weatherman et al.
Mol. Endocrinol. 2002;16:487-496.
ABSTRACT | FULL TEXT  

Expression of Gonadotropin Receptor and Growth Responses to Key Reproductive Hormones in Normal and Malignant Human Ovarian Surface Epithelial Cells
Syed et al.
Cancer Res. 2001;61:6768-6776.
ABSTRACT | FULL TEXT  

Parity, Oral Contraceptives, and the Risk of Ovarian Cancer among Carriers and Noncarriers of a BRCA1 or BRCA2 Mutation
Modan et al.
NEJM 2001;345:235-240.
ABSTRACT | FULL TEXT  

Relationship Between Postmenopausal Hormone Replacement Therapy and Ovarian Cancer
Bosetti et al.
JAMA 2001;285:3089-3090.
FULL TEXT  

Does Menopausal Estrogen Therapy Increase Risk for Dying from Ovarian Cancer?
JWatch Women's Health 2001;2001:4-4.
FULL TEXT  

Does Estrogen Replacement Therapy Increase Ovarian Cancer Risk?
JWatch General 2001;2001:1-1.
FULL TEXT  

Women's Health--Filling the Gaps
DeAngelis and Winker
JAMA 2001;285:1508-1509.
FULL TEXT